Study Shows Limits of Rapid Antibiotic Susceptibility Testing

Why It Matters

The findings temper expectations for rapid testing as a universal solution, highlighting its niche value for resistant infections and informing stewardship strategies in hospitals.

Key Takeaways

• FAST trial enrolled 850 patients across four countries.
• Rapid testing cut escalation time by 14 hours but didn't improve outcomes.
• DOOR favorability 48.8% fell short of 50% superiority threshold.
• Carbapenem‑resistant cases saw fewer prolonged hospital stays.

Pulse Analysis

Rapid antimicrobial susceptibility testing promises to shrink the two‑day lag inherent in conventional blood‑culture workflows, a delay that forces clinicians to rely on broad‑spectrum empiric therapy. By delivering organism‑specific susceptibility data within hours, such tools could theoretically curb unnecessary antibiotic exposure, reduce resistance pressure, and improve patient safety. However, the technology’s real‑world impact depends on how quickly stewardship teams can act on the information and whether the clinical benefit outweighs added costs.

The FAST trial, presented at ESCMID Global, randomized more than 800 adults and children across Greece, India, Israel, and Spain to receive either rapid Vitek Reveal testing plus standard culture or standard culture alone. While the rapid arm accelerated the median time to antibiotic escalation or de‑escalation by 14 hours, the composite desirability‑of‑outcome ranking (DOOR) showed a 48.8% probability of a better outcome—below the pre‑specified 50% superiority benchmark. Mortality, overall length of stay, and most secondary endpoints were statistically indistinguishable, underscoring that faster data alone does not automatically translate into improved survival.

For health systems, the trial’s nuanced results suggest a targeted deployment of rapid testing may be prudent, focusing on high‑risk cohorts such as patients with carbapenem‑resistant organisms or septic shock where timely therapy adjustments are most critical. Ongoing cost‑benefit analyses will determine whether the incremental expense of rapid platforms is justified by reductions in prolonged admissions and downstream resistance. As antimicrobial stewardship programs mature, integrating rapid diagnostics with robust decision‑support pathways could unlock the technology’s full potential, shaping a more precise, patient‑centered approach to sepsis management.